

Media round-up live: Heard virtually around the social media square

12:35am - 1:35am Biotech Showcase

As the most important week of the biotech calendar draws to a close, join us to hear what trends and issues this panel of journalists think will reverberate in 2021.

Participants

Moderator: Kimberly Ha - CEO and Founder, KKH Advisors

Panelist: Alaric DeArment - Reporter, Scrip

Panelist: Moira Gunn - Host of Tech Nation and Professor, NPR, University of San Francisco

Panelist: Virginia Li - Associate Editor, BioCentury

Panelist: Sony Salzman - Coordinating Producer, Medical Unit ABC

OPEN SESSION - Diversity: Investing in diversity

On demand Biotech Showcase

It has become clear that diversity in all forms — ethnic, racial, gender, age — leads organizations to greater success. We know that different perspectives and experiences create more opportunities. Join us to hear what our industry is doing to invest in diversity, a powerful resource.

Sign up for this session here

Participants

Moderator: Paul J. Hastings - President and CEO, Nkarta Therapeutics, Inc. (NASDAQ GS: NKTX)

Panelist: Lucy Abreu - Senior VP, Diversity, Equity and Inclusion Strategist and Employee Engagement Lead, Syneos Health Communications

Panelist: Julia Levy - Founder and Former CEO, QLT Inc.

Panelist: Anthony Sun - CEO, Zentalis Pharmaceuticals (NASDAQ: ZNTL)

Panelist: Meg Zweig - COO, Rock Health

Let's Discuss Women's Healthcare: An undertapped investment opportunity

On demand Biotech Showcase

According to a report by Frost & Sullivan, the Women's Health markets will reach \$1.10 bn in revenue by 2024 with the potential of crossing \$9 bn in 2024. The market potential is significant although market penetration remains low at this time. It is time for the investor class to pay serious attention to this sector.

Participants

Moderator: Jennifer Friel Goldstein - Managing Partner, Life Science and Healthcare, SVB Capital

Panelist: Berthold Hinzen - VP and Head of Business Development and Licensing, Therapeutic Areas, Bayer

Panelist: Taja Lester - Managing Partner, Health Equity Capital

Panelist: Gail Maderis - President and CEO, Antiva Biosciences

Panelist: Debora Spar - Professor and Senior Associate Dean, Harvard Business School

Cardiovascular and nephrology: a renewed interest

On demand Biotech Showcase

Drug development in nephrology and cardiovascular specialties have had a revival of venture investments in recent years, after facing headwinds regarding capital-intensive trials and a challenging reimbursement landscape. During the panel discussion, we will touch upon topics including the tailwinds in the space from the perspectives of investment, advancements in the scientific body of knowledge, clinical development and regulatory approaches.

Participants

Moderator: Bibhash Mukhopadhyay - Principal, New Enterprise Associates (NEA)

Panelist: Philippe Alen - Head of Cardiovascular Business Development Licensing & Alliance Management, Bayer SA-NV

Panelist: Grace Colon - CEO, InCarda Therapeutics Inc.

Panelist: Arthur Klausner - President and CEO, Goldilocks Therapeutics, Inc.

Cell and gene therapy

On demand Biotech Showcase

The key driver for success is figuring out the unique manufacturing process and how to scale to market. How are companies approaching this challenge?

Participants

Moderator: Mani Foroohar - Managing Director and Senior Research Analyst, SVB Leerink

Panelist: Arjun Goyal - Co-Founder and Managing Director, Vida Ventures

Panelist: Rachel Haurwitz - President and CEO, Caribou Biosciences. Inc.

Panelist: Rachelle Jacques - CEO, Enzyvant

Panelist: Jak Knowles - CBO, Metagenomi

Panelist: Geoff MacKay - CEO, AVROBIO (NASDAQ: AVRO)

CNS: Following the innovation

On demand Biotech Showcase

A broad perspective exploring new breakthroughs in research and drug discovery for one of the most challenging therapeutic areas. From expanded therapy options for epilepsy and Altzheimer's to novel treatments for depression to the new technologies researchers use to power these discoveries, this panel will explore key challenges and innovations across CNS

Participants

Moderator: Marc Goodman - Managing Director, SVB Leerink Equity Research, Neuroscience

Panelist: Phyllis Barkman - Global Head, External Engagement, Alzheimer's disease and Neurodegeneration, Eli Lilly & Company

Panelist: Kyle Gano - Chief Business Development and Strategy Officer, Neurocrine Biosciences (NASDAQ: NBIX)

Panelist: Abraham Heifets - Co-Founder and CEO, Atomwise

Panelist: Tracy Saxton - Managing Director, Dolby Family Ventures

SESSIONS BIOTECH SHOWCASE ON DEMAND -

Official event dates: January 11-15, 2021 Post-show access until March 31, 2021

Diagnostics: The coming of age of diagnostics

On demand **Biotech Showcase**

An unintended consequence of COVID-19 has been the increase in attention being paid to the need for quick and accurate diagnostics for COVID-19 and beyond. Investors, pharma and biotech are taking note.

Participants

Moderator: Steve Dickman - CEO, CBT Advisors

Panelist: Rahul Dhanda - Co-Founder and CEO,

Sherlock Biosciences

Panelist: Jeff Hawkins - CEO. Truvian Health

Panelist: Madeline Repollet - Head of Clinical

Laboratories, ANGLE plc

Panelist: Ajit Singh - Partner, Artiman Ventures

Oncology: The in-rush of funds for IO and non-

On demand **Biotech Showcase**

Oncology continues to be a leading category for both funding and partnerships, with a balance between IO and non-IO. There is a renewed focus on small molecules developed via a precision medicine and more drugs are moving through development faster. And, while there are plenty of me-too-like strategies, there continues to be great innovation around MOAs and platforms. What is driving the investor and partner interest?

Participants

Moderator: Jeffrey Bockman - Executive VP and Oncology Practice Head, Cello Health BioConsulting

Panelist: Asthika Goonewardene - Managing Director and Senior Analyst, Truist Securities

Panelist: Taylor Guo - Co-Founder and CSO, I-Mab Biopharma

Panelist: Matthias Müllenbeck - Executive Director & Head Global Licensing and Business Development Enabling Technologies Biopharma, Global Business Development and Alliance Management, Merck KGaA, Darmstadt, Germany

Panelist: Christopher Mortko - Associate VP, Merck & Co Inc.

Panelist: Laura Stoppel - Principal, RA Capital Management

In conversation with the COVID-19 leaders: A sense of urgency and collaboration

On demand **Biotech Showcase**

The BioPharma industry has been front and center in developing vaccines for COVID-19, accelerating development at breakneck speed and demonstrating what is possible in drug development. The insights and firsthand experience of rising to the occasion to address this urgent need.

Participants

Moderator: Paul Colvin - President, Clinical Solutions, Syneos Health

Panelist: Kumar Srinivasan - VP and Global Head of Business Development and Licensing, BioPharmaceuticals R&D, AstraZeneca Pharmaceuticals

Clinical Studies in 2021: The changing dynamics and challenges of getting studies done rapidly

On demand Biotech Showcase - INSIGHTS

The COVID-19 pandemic has accelerated the pace at which our industry innovates. Studies around the world have been faced with unprecedented challenges in trial delays and balancing safety with speed on critical research. Join Andrew Schachter, Founder and CEO of Axiom Real-Time Metrics, as he shares insights on how Axiom has been able to successfully support client trial continuity in 20 countries, implement essential remote trial solutions like ePRO and eSource, and keep timelines on track with a rapid study start-up approach. With a key focus on data-driven studies, eClinical Solutions are more important than ever when it comes to enabling sponsors and team members to be aware of critical data and operational issues, trends and potential solutions.

Participants

Moderator: Ben Bonifant - Partner, Triangle Insights

Panelist: Andrew Schachter - Founder and CEO, Axiom Real-Time Metrics

Patients first: A path to better outcomes for everyone

On demand

Biotech Showcase - INSIGHTS

How incorporating insights about patients and their lives into trial planning and design helps avoid unnecessary protocol amendments and facilitates recruitment and retention. In addition, utilizing the latest innovations makes it easier for patients to participate in trials and empowers them to be more active participants.

Participants

Moderator: Ted Haack - VP, Lattice Point Consulting

Panelist: Peyton Howell - Executive VP, CCO and CSO, Parexel

Part 1 - The world according to COVID-19: From crisis to long-term impact

On demand **Biotech Showcase**

Participants

Moderator: Leah Rosenbaum - Assistant Editor, Healthcare & Science, Forbes

Panelist: Jeremy Levin - CEO, Ovid Therapeutics; Board of Directors Chair, Biotechnology Innovation Organization (BIO)

Panelist: Michelle McMurry-Heath - President and CEO. Biotechnology Innovation Organization (BIO)

The Anatomy of an Acquisition: Bayer and **AskBio**

On demand

Biotech Showcase - INSIGHTS

The acquisition of AskBio is a historical deal, not only because of the size of the deal, but also its strategic relevance. With Bayer consolidating its presence in the Cell and Gene Therapy space, partnering with AskBio presents a unique opportunity to lead the genomic medicine space. There are multiple elements that made this deal a success: record-breaking dealmaking speed during a global pandemic, joint development of milestones that align interests, and a unique operating model that safeguards AskBio's independence are just a few of the critical success factors. Join Marianne De Backer and Sheila Mikhail for a fireside chat and learn more about the insights of the acquisition.

Participants

Moderator: Stephanie Léouzon - Partner and Head, Torreya Europe

Panelist: Marianne De Backer - Executive VP, Head of Strategy, Business Development & Licensing and Executive Committee Member, Bayer AG, Pharmaceuticals

Panelist: Sheila A. Mikhail - Co-Founder and CEO. Asklepios BioPharmaceutical, Inc. (AskBio)



Hindsight is 2020: Lessons learned from DCTs and 2021 predictions

On demand Biotech Showcase - INSIGHTS

2020 has been a remarkable year for health, drug development, and decentralized connectivity with over 1 million people around the world engaging with Medable applications. In this session we'll offer insights to: •DCT foundations and priorities •DCT ecosystems, enabling a unified, seamless experience •Case studies, metrics, and lessons learned

Participants

Panelist: Alison Holland - Head of Decentralized and Remote Trials, Medable

Panelist: Craig Lipset - Managing Partner, Clinical Innovation Partners LLC

Part 2 - The world according to COVID-19: Inside Operation Warp Speed

On demand Biotech Showcase

Participants

Moderator: Michelle McMurry-Heath - President and CEO, Biotechnology Innovation Organization (BIO)

Moderator: Jeremy Levin - CEO, Ovid Therapeutics; Board of Directors Chair, Biotechnology Innovation Organization (BIO)

Panelist: Moncef Slaoui - Scientific Head, Operation Warp Speed

Endless Frontier Labs - A model for success

On demand Biotech Showcase - INSIGHTS

Participants

Moderator: Linda Brown - Advisory Board Member, New Jersey Bioscience Center Incubator

Panelist: Deepak Hegde - Associate Professor of Management and Organizations and Director, Endless Frontier Labs, New York University, Stern School of Business

Panelist: Robert J. Schneider - Albert Sabin Professor of Molecular Pathogenesis, NYU School of Medicine, Alexandria Center for Life Sciences

In conversation with the COVID-19 leaders: In the balance — the humanitarian perspective - global policy

On demand Biotech Showcase

We all believed we would find a vaccine, but that is the easy part. Now that we have a few (hopefully) vaccines approved and being manufactured, how do we get the vaccine to the people most in need.

Participants

Moderator: Jeremy Abbate - Publisher, Scientific American

Moderator: Ruxandra Draghia-Akli - Global Head, Johnson & Johnson Global Public Health R&D

Panelist: Amy Finan - CEO, Sabin Vaccine Institute

Panelist: Richard Hatchett - CEO, CEPI

In conversation with the COVID-19 leaders: COVID-19 therapeutics: A review of the options

On demand Biotech Showcase

Participants

Moderator: Stephen G. Brozak - Managing Partner and President, WBB Securities LLC

Panelist: Prabhavathi Fernandes - Chair, National Biodefense Science Board

Panelist: Michael Kurilla - Director of Division of Clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health

Post-election policy and drug development: now what?

On demand Biotech Showcase

Post-election policy and drug development: now what?

Participants

Moderator: Alice Valder Curran - Partner, Hogan Lovells

Panelist: Julie Gerberding - Executive VP and Chief Patient Officer, Merck & Co. Inc.

Panelist: Peter Kolchinsky - Founder and Managing Partner, RA Capital Management

Panelist: Greg Simon - Consultant, Simonovation LLC

In conversation with the COVID-19 leaders: Fulfilling the manufacturing promise for the global supply chain

On demand Biotech Showcase

Participants

Moderator: Melissa Fassbender - Former Journalist, Associate Director of External Communications, Polsky Center for Entrepreneurship & Innovation, University of Chicago

Panelist: Katherine Eban - Contributing Editor, Investigative Journalist, Author: Bottle of Lies: the Inside Story of the Generic Drug Boom, Vanity Fair

Panelist: Robin Robinson - CSO and Founding Director, RenovaCare, BARDA

In conversation with the COVID-19 leaders: The path forward

On demand Biotech Showcase

Participants

Moderator: Sara Jane Demy - CEO and Founder, Demy-Colton

Panelist: Rick Bright - Former Director, Biomedical Advanced Research and Development Authority (BARDA), Transition Team, COVID-19 Advisory Board

The pharma perspective: The unintended positive consequences of COVID-19

On demand Biotech Showcase

Collaborations, business development and accelerating drug development. Roles and responsibilities of the pharma industry in times of pandemic.

Participants

Moderator: Sam Fazeli - Director of EMEA Research and Senior Pharmaceutical Analyst, Bl, Bloomberg L.P.

Panelist: Marianne De Backer - Executive VP, Head of Strategy, Business Development & Licensing and Executive Committee Member, Bayer AG, Pharmaceuticals

Panelist: Shaun Grady - Senior VP of Business Development Operations, AstraZeneca

Panelist: Leanne Larson - Senior VP, Real-World Evidence & Access, Parexel

Panelist: Philippe Lopes-Fernandes - Executive VP and CBO, Ipsen

Panelist: John McDonald - Corporate VP and Global Head Business Development, Novo Nordisk



The year of the IPO and the coming of age of the SPACs

On demand Biotech Showcase

Already four dozen biotech IPOs this year and it is only September, netting the sector more than \$11 billion.

Participants

Moderator: William Kolb - Partner, Foley Hoag

Panelist: Gabriel P. Cavazos - Managing Director, Investment Banking, SVB Leerink

Panelist: Paul J. Hastings - President and CEO, Nkarta Therapeutics, Inc. (NASDAQ GS: NKTX)

Panelist: Art Pappas - Managing Partner, Pappas Capital

Panelist: Scott Platshon - Principal, EcoR1 Capital

Panelist: Laura Shawver - CEO, Silverback Therapeutics (NASDAQ: SBTX)

In conversation with the COVID-19 leaders: The Novavax COVID-19 Journey

On demand Biotech Showcase

Participants

Moderator: Kimberly Ha - CEO and Founder, KKH Advisors

 $\mbox{\bf Panelist: John J. Trizzino} \mbox{-} \mbox{Executive VP, CCO and CBO, Novavax}$

In conversation with the COVID-19 leaders: The UK perspective

On demand Biotech Showcase

Participants

Moderator: Jaime E. Hernandez - Executive Medical Director, Infectious Disease and Vaccines, Syneos Health

Panelist: Steve Bates - CEO, BioIndustry Association

Panelist: Kate Bingham - Former Chair U.K. Vaccine Taskforce, Managing Partner, SV Health Managers LLP

Value creation and venture

On demand Biotech Showcase

Biopharma company financing has surged this year with venture funding in 2020, surpassing 2019 numbers. In a world of uncertainty, what are the fundamentals driving value?

Participants

Moderator: Jeff Cranmer - BioCentury Inc., BioCentury Inc.

Panelist: Eric Aguiar - Partner, Aisling Capital LLC

Panelist: Marian T. Nakada - VP Venture Investments, Johnson & Johnson Innovation, JJDC

Panelist: Rafaèle Tordjman - Founder and CEO, Jeito Capital

Panelist: Stella Xu - Managing Director, Quan Capital

The Investors' View: Where is the money going in 2021?

On demand Biotech Showcase

Participants

Moderator: Dennis J. Purcell - Founder and Senior Advisor, Aisling Capital

Panelist: Mara Goldstein - Managing Director, Mizuho Securities USA

Panelist: Nina Kjellson - General Partner, Canaan

Panelist: Camille Samuels - Partner, Venrock

Infectious Disease - COVID-19 Vaccines: All things impacted by COVID-19: The pursuit for an effective vaccine developed at a pandemic pace

On demand Biotech Showcase

Multiple approaches and different platforms for developing a COVID-19 vaccine and the associated benefits and challenges with each one, from research, development, approval, scalability and manufacturing to cold chain logistics. Where are we at today and what are the next milestones.

Participants

Moderator: Yasmeen Rahimi - Senior Research Analyst, Piper Sandler

Panelist: Sean Marett - CBO and CCO, BioNtech (NASDAQ: BNTX)

Panelist: Joseph Payne - President and CEO, Arcturus Therapeutics. Inc.

Panelist: Scot Roberts - CSO, Altimmune (NASDAQ: ALT)

OPEN SESSION - From de-risking to value creation - The evolving role of patient communities in rare disease drug development and commercialization

On demand Rare Beyond the Square

As patient communities and advocacy leaders become more deeply embedded in drug development, especially in rare diseases, it is imperative that organizations understand how patient engagement drives value beyond de-risking. Hear insights on how patients are changing the landscape for the development of novel therapeutics and how researchers, drug developers and funders can better leverage patient-centric approaches to optimize value throughout development. Delve into how patient advocacy engagement in drug development can act as a driver of investor value and learn how patient advocates are becoming market makers. This panel will take place as part of RARE Beyond the Square at Biotech Showcase hosted by Global Genes

Sign up for this session here

Participants

Moderator: Sara Nayeem - Partner, NEA

Panelist: Dave Greenwald - VP, Deerfield Management

Panelist: Rich Horgan - Founder, Cure Rare Disease

Panelist: Vijay Sappani - Founder and CEO, Ela Capital,

CDG Canada

Panelist: Walt Kowtoniuk - Partner, Third Rock

To spend or not to spend: Investing for commercial success as an emerging company

On demand Biotech Showcase

Participants

Workshop Leader: Naveen Murthy - Senior Managing Director and Head of Product & Franchise Strategy, Commercial Advisory Group, Consulting, Syneos Health

Workshop Leader: Sachin Purwar - Director of Commercial Advisory Group, Consulting, Syneos Health

Workshop Leader: Michael Sarshad - Director of Commercial Advisory Group, Consulting, Syneos Health

Panelist: Ram Aiyar - CEO, Korro Bio

Panelist: Adele Gulfo - CBO and Commercial Development Officer, Sumitovant Biopharma

Panelist: Aziz Mottiwala - CCO, Tarsus Pharmaceuticals

Panelist: Vicki Vakiener - CCO, Epizyme

SESSIONS
BIOTECH SHOWCASE ON DEMAND -

Official event dates: January 11–15, 2021 Post-show access until March 31, 2021

A film selection from The Disorder Channel: Unfixed - Covid: How We're Affected

On demand Rare Beyond the Square

The Unfixed series of films, as seen on The Disorder Channel, illustrates how COVID-19 has affected rare families from the lenses of Body, Mind, and Spirit. Biotech Showcase registrants will have special access to view the film "Unfixed: Unfixed - Covid: How We're Affected" on-demand in early January 2021 and through the conclusion of the conference in partneringONE. The Unfixed series of films address Tourettes, Chrons, trigemial neuralgia, Mal de debarquement, ALS, Parkinsons, narcolepsy, fibromyalgia, TBI, synkinesis, transverse myelitis, polycythemia vera, asthma, and EDS. This film is included as part of RARE Beyond the Square program at Biotech Showcase hosted by Global Genes.

Thank you to the RARE Beyond the Square sponsors for supporting this experience: bluebird bio, Charles River, Cure Rare Disease, Deerfield Management, Ovid Therapeutics, Sarepta Therapeutics, UCB & Vertex Pharmaceuticals.

Alliance for Regenerative Medicine's annual cell & gene state of the industry briefing

On demand Biotech Showcase

ARM's annual yearly update on the sector's progress, followed by a panel session featuring top CEOs and executives highlighting future inflection points for cell and gene therapies in the coming year.

Participants

Speaker: Janet Lambert - CEO, Alliance for Regenerative Medicine

Leveraging platform approaches to gene therapies to accelerate therapeutic development for monogenic diseases

On demand Rare Beyond the Square

While rare disease therapeutic development has accelerated in recent years and continues to be a major focus for biopharmaceutical companies and investors, 95%+ of rare diseases are still lacking an approved therapy or treatment. Hear how platform approaches to gene therapies and editing have the potential to enable a more scalable, and inherently patient-centric, approach to clinical development. This panel will take place as part of RARE Beyond the Square at Biotech Showcase hosted by Global Genes

Participants

Moderator: Allyson Berent - CSO and COO, Foundation for Angelman Syndrome Therapeutics, GeneTx Biotherapeutics

Panelist: P.J. Brooks - Program Director, Office of Rare Diseases Research, National Center for Advancing Translational Sciences (NCATS), NIH

Panelist: Nicole Guadelli - Director and Head of Gene Editing Technologies, Beam Therapeutics

Panelist: Nick Leschly - Chief Bluebird, bluebird bio

Panelist: Peter Marks - Director of Center for Biologics Evaluation and Research, U.S. Food and Drug Administration

Looking Ahead – What to expect for the cell & gene therapy sector in 2021 and beyond

On demand Biotech Showcase

Participants

Speaker: Janet Lambert - CEO, Alliance for Regenerative Medicine

Moderator: Terry-Ann Burrell - CFO, Beam Therapeutics

Panelist: Marianne De Backer - Executive VP, Head of Strategy, Business Development & Licensing and Executive Committee Member, Bayer AG, Pharmaceuticals

Panelist: Sandy Macrae - President & CEO, Sangamo Therapeutics

Panelist: Ken Mills - President and CEO, REGENXBIO

Panelist: Adrian Rawcliffe - CEO, Adaptimmune

Advancing patient-centered value frameworks for novel therapeutics in rare disease

On demand Rare Beyond the Square

While scientific advances have enabled the development of novel therapeutics to tackle genetic and rare diseases, healthcare infrastructure has struggled to keep pace in providing sustainable pathways to access for patients receiving them. Compounded with the high cost of development with limited markets, this has created an increasingly complex landscape for rare disease patients and companies looking to gain market access for their products. Hear about the current landscape for rare disease reimbursement access, where key challenges exist in developing sustainable pathways, and what types of new value frameworks and assessment models are being discussed to address them. This panel will take place as part of RARE Beyond the Square at Biotech Showcase hosted by Global Genes.

Participants

Panelist: Diane Berry - Senior VP, Global Health Policy, Government and Patient Affairs, Sarepta Therapeutics

Panelist: Donna Cryer - President and CEO, Global Liver Institute

Panelist: Jeremy Levin - CEO, Ovid Therapeutics; Board of Directors Chair, Biotechnology Innovation Organization (BIO)



TIME	BIOTECH SHOWCASE	BIOTECH SHOWCASE - INSIGHTS	RARE BEYOND THE SQUARE
12:00AM	12:35am - Media round-up live: Heard virtually around the social media square		
1:00AM			
2:00AM			
3:00AM			
4:00AM			
5:00AM			
6:00AM	On demand - OPEN SESSION - Diversity: Investing in diversity On demand - Let's Discuss Women's Healthcare: An under-tapped investment opportunity On demand - Cardiovascular and nephrology: a renewed interest On demand - Cell and gene therapy On demand - CNS: Following the innovation On demand - Diagnostics: The coming of age of diagnostics On demand - Oncology: The in-rush of funds for IO and non-IO On demand - In conversation with the COVID-19 leaders: A sense of urgency and collaboration	On demand - Clinical Studies in 2021: The changing dynamics and challenges of getting studies done rapidly	
7:00AM	On demand - Part 1 - The world according to COVID-19: From crisis to long-term impact	On demand - Patients first: A path to better outcomes for everyone On demand - The Anatomy of an Acquisition: Bayer and AskBio	
8:00AM	On demand - Part 2 - The world according to COVID-19: Inside Operation Warp Speed	On demand - Hindsight is 2020: Lessons learned from DCTs and 2021 predictions	
9:00AM	On demand - In conversation with the COVID-19 leaders: In the balance — the humanitarian perspective - global policy	On demand - Endless Frontier Labs - A model for success	
10:00AM	On demand - In conversation with the COVID-19 leaders: COVID-19 therapeutics: A review of the options		
11:00AM	On demand - Post-election policy and drug development: now what?		





TIME	BIOTECH SHOWCASE	BIOTECH SHOWCASE - INSIGHTS	RARE BEYOND THE SQUARE
12:00PM	On demand - In conversation with the COVID-19 leaders: Fulfilling the manufac- turing promise for the global supply chain		
1:00PM	On demand - In conversation with the COVID-19 leaders: The path forward		
2:00PM	On demand - The pharma perspective: The unintended positive consequences of COVID-19		
3:00PM	On demand - The year of the IPO and the coming of age of the SPACs		
4:00PM	On demand - In conversation with the COVID-19 leaders: The Novavax COVID-19 Journey		
5:00PM	On demand - In conversation with the COVID-19 leaders: The UK perspective		
6:00PM	On demand - Value creation and venture		
7:00PM	On demand - The Investors' View: Where is the money going in 2021?		
8:00PM	On demand - Infectious Disease - COVID-19 Vaccines: All things impacted by COVID-19: The pursuit for an effective vaccine developed at a pandemic pace		On demand - OPEN SESSION - From derisking to value creation – The evolving role of patient communities in rare disease drug development and commercialization
9:00PM	On demand - To spend or not to spend: Investing for commercial success as an emerging company		On demand - A film selection from The Disorder Channel: Unfixed - Covid: How We're Affected
10:00PM	On demand - Alliance for Regenerative Medicine's annual cell & gene state of the industry briefing		On demand - Leveraging platform approaches to gene therapies to accelerate therapeutic development for monogenic diseases
11:00PM			



SESSIONS
CHINA SHOWCASE ON DEMAND -

Official event dates: January 11–15, 2021 Post-show access until March 31, 2021

Partnering: One-to-one meetings

8:30am - 7:30am One-to-one meetings

One-to-one meetings will be available to schedule online for 24 hours on January 10

Keynote: The state of China life science

8:40am - 9:40am China Showcase - ON DEMAND

Participants

Speaker: Greg Scott - Founder and Chairman, ChinaBio® Group

Looking ahead – what to expect in the new world order

On demand China Showcase - ON DEMAND

Despite COVID-19's devastating impact on lives and economies around the world, the virus spurred growth in the biopharma sector. Investments and deals continue to be robust, especially in China. As the healthcare market in China continues to grow, companies seeking to launch or expand there are strategically placing their bets to maximize growth opportunities. Industry experts share their insights on areas of growth and expectations for the year ahead.

Participants

Moderator: Greg Scott - Founder and Chairman, ChinaBio® Group

Panelist: Betty Huang - Head of Business Development and Licensing for China/APAC, Bayer AG

Panelist: Amy Tang - Venture Partner, Qiming Venture Partners.

Panelist: Victor E. Tong, Jr. - Partner, Decheng Capital

Panelist: PC Zhu, Ph.D - Founder and CEO, ATLATL Innovation Center

Accelerating innovation

On demand China Showcase - ON DEMAND

Exciting new business models are bringing together technology, talent, funding, partners and other resources to accelerate the development of innovative products. How are investors and MNCs breaking the mold to efficiently and effectively develop new products, create new companies, support entrepreneurs?

Participants

Moderator: Kimberly Nearing - Venture Partner, BVCF

Panelist: Sujuan Ba - CEO, National Foundation for Cancer Research

Panelist: Tony Chen - Partner, Jones Day

Panelist: Will Liu, PhD - Partner, Eight Roads Ventures

Panelist: Brad Loncar - CEO, Loncar Investments

Panelist: Alex Zhang, PhD - CEO, Hanhai Silicon Valley

Bigger deals, higher valuations, greater access to capital

On demand China Showcase - ON DEMAND

The biopharma industry continues to fare well in the global capital markets, providing companies with opportunities to raise impressive funding rounds and launch impressive IPOs. Whether in Shanghai, New York or Hong Kong, the sector is hot with 796 deals generating \$27.62 Billion in investments through Q3 2020*, including two of the world's largest IPOs. What are some of the key factors to determining when and where to raise capital? Leading company executives share their insights on navigating the road to success. * S&P Global Market Intelligence

Participants

Moderator: Brian Yang - Senior Editor, China Head, Informa Business Intelligence

Panelist: Joan Huaqiong Shen, M.D., Ph.D. - CEO, I-Mab Biopharma

Panelist: Fang Jianmin, Ph.D. - Founder and CEO, RemeGen

Panelist: James Li, M.D. - Co-Founder and CEO, JW Therapeutics

Cross-border collaboration considerations

On demand

China Showcase - ON DEMAND

For successful partnerships between companies in China, EU and the US, what best practices should be adopted and what pitfalls should be avoided? What strategies are companies employing to tap into opportunities outside of their borders? Why is it important to secure a partner in China and what does it take to do so successfully? Expert deal-makers provide guidance on ways to facilitate deals.

Participants

Moderator: Robert Narquizian - Managing Director, ChinaBio® Group

Panelist: Michael Chen, PhD - Head of Business Development, Akeso Biopharma, Inc.

Panelist: Ming Fang, PhD - Head of Business Development, Elpiscience Biopharma

Panelist: Frank Grams, PhD - SVP Alliance Management and Head BD Europe, Everest Medicines

Panelist: Kathy He - CBO, Kira Pharmaceuticals

Spotlight on China's next wave of leading companies

On demand

China Showcase - ON DEMAND

Innovative companies developing new therapeutics, platform technologies and AI & digital health tools share their strategies in expanding their innovations through international partnerships

Participants

Panelist: Darren Ji - Chairman and CEO, Elpiscience





TIME	CHINA SHOWCASE - ON DEMAND	ONE-TO-ONE MEETINGS
8:00AM	8:40am - Keynote: The state of China life science	8:30am - Partnering: One-to-one meetings
9:00AM	On demand - Looking ahead – what to expect in the new world order	
10:00AM	On demand - Accelerating innovation	
11:00AM	On demand - Bigger deals, higher valuations, greater access to capital	
12:00PM	On demand - Cross-border collaboration considerations	
1:00PM	On demand - Spotlight on China's next wave of leading companies	

SESSIONS

DIGITAL MEDICINE AND MEDTECH SHOWCASE ON DEMAND -

Biotech Showcase

Official event dates: January 11–15, 2021 Post-show access until March 31, 2021

Digital tools revolutionizing mental health treatment

On demand

Digital Medicine & Medtech Showcase

Participants

Moderator: Katherine Harris - Associate, Silicon Valley Bank

Panelist: Liz Rockett - Managing Director, Kaiser Permanente Ventures

Panelist: Danielle Schlosser - Head and Behavioral Health Lead, Verily Life Sciences, an Alphabet Company

Panelist: Solome Tibebu - Founder, Going Digital: Behavioral Health Tech

Panelist: Chris Wasden - Head of HappifyDTx, Happify Health

Interview with the FDA's Bakul Patel

On demand

Digital Medicine & Medtech Showcase

In this fireside chat style interview, the Director of the FDA's Digital Health Center of Excellence, Bakul Patel, and McDermott Will & Emery's FDA Practice Chair Vernessa Pollard will share perspectives on recent regulatory and market developments for digital health, digital therapies and innovative technologies and the implications for patients, healthcare providers and other stakeholders.

Participants

Interviewer: Vernessa Pollard - Partner and Chair, McDermott Will & Emery, FDA Practice

Speaker: Bakul Patel - Director of Digital Health Center of Excellence, Food and Drug Administration

Interview with Venrock's Bryan Roberts

On demand

Digital Medicine & Medtech Showcase

Venture capitalist Bryan Roberts, general partner with Venrock, rides technology and investing waves to deliver multiple billion dollar exits. As an investor, what trends does he have his eye on?

Participants

Interviewer: Moira Gunn - Host of Tech Nation and Professor, NPR, University of San Francisco

Speaker: Bryan Roberts - Partner, Venrock

Interview with Medable's Michelle Longmire

On demand

Digital Medicine & Medtech Showcase

Direct-to-patient technologies are redefining the healthcare landscape. Learn how mobile technologies will usher in a new era of healthcare where patients exert more control and physicians expand how they can interact with patients.

Participants

Moderator: Sari Kaganoff - General Manager of Consulting, Rock Health

Panelist: Michelle Longmire - Founder and CEO, Medable

Investment, Commercialization, and Value Recognition: The Al Healthcare Hurdle

On demand

Digital Medicine & Medtech Showcase

There was a point in the last five years that simply putting "AI" in a company name immediately demanded unicorn level investments. As the field has progressed, and now is widely recognized as possessing vast potential, AI-enabled healthcare investors, innovators and entrepreneurs struggle to answer the seemingly simple question of "What are we making?". This panel will consider the challenges, opportunities, and nuances of investing in and creating value around this new generation of discovery and development tools. Representing both sides of the coin, investor and fundraiser, panelists will seek to answer these questions among others to guide future stakeholders in navigating this complex issue.

Participants

Panelist: Harry Glorikian - General Partner, Scientia Ventures

Panelist: Angeli Moeller - Appointed Head of Pharma Informatics International, Roche

Panelist: Dylan Morris - General Partner, CRV

Panelist: John Vandermosten - Senior Biotechnology Analyst, Zacks Small Cap Research

Panelist: Vangelis Vergetis - CEO, Intelligencia Inc.

Medtech's role in a transformed future

On demand

Digital Medicine & Medtech Showcase

As the medtech and digital health sectors converge, COVID-19 has accelerated the need for advancements in medtech solutions. This panel will examine what is spurring tech innovation now, what innovations are going to continue transforming health care in the long term, and how investment and partnering strategies are driving successful business models to deliver those innovations.

Participants

Moderator: Andrew Fish - CSO, AdvaMed

Panelist: Rubal Bedi - Global Head and VP of Corporate Venture Group, HOYA

Panelist: Tak Cheung - Principal, New Enterprise Associates (NEA)

Panelist: Tom Shebab - Managing Partner, Arboretum Ventures

ventures

Panelist: Renee Ryan - CEO, Cala Health

Other doors: Backdoors, side doors, and alternative ways to fund and partner your technology

On demand

Digital Medicine & Medtech Showcase

From the inner space of neural nets to the outer space of space medicine these panelists source, fund, partner and bridge the distance between government agencies and institutions needing cutting edge health technology and the companies that can provide it. These panelists are translators who serve as bridges between the worlds of medical technologies and the institutions looking for them. In this session, they explain how these unique investment and partnerships work and how to access them.

Participants

Moderator: Joanna Schulman - CEO, AIDIA Collective

Panelist: Dan Hanfling - VP, In-Q-Tel

Panelist: James Hury - CIO, Translational Research Institute for Space Health

Panelist: Armen Kherlopian - Co-Founder, BAJ Accelerator

Panelist: Danielle Peters - President, Magnet Strategy Group Cross-Border Health Foundation

SESSIONS

DIGITAL MEDICINE AND MEDTECH SHOWCASE ON DEMAND -

Official event dates: January 11–15, 2021 Post-show access until March 31, 2021

Telemedicine: Enabling virtual and hybrid care post COVID-19

On demand

Digital Medicine & Medtech Showcase

Telemedicine was put on the fast track playing a critical role in delivering healthcare during the early days of the COVID-19 pandemic and it's here to stay. This panel will explore how providers and patients will continue to engage with one another after the COVID-19 pandemic relying on virtual and hybrid care as normal modalities of care.

Participants

Moderator: Lisa Mazur - Partner, McDermott Will & Emery

Panelist: Hill Ferguson - CEO, DoctorOnDemand

Panelist: Leslie Haas - Manager of Digital Health Strategy, Stanford Health Care

Panelist: David J. Kim - Managing Director, DigiTx Partners

Panelist: Dhruv Vig - VP, Silicon Valley Bank

The digitization of clinical trials

4:30pm - 5:30pm Digital Medicine & Medtech Showcase

COVID-19 accelerated the adoption of decentralized clinical trials (DCT) and use of digital health/Al tools to support clinical trials. This panel will explore the new technologies increasing access to clinical trials and partnership and investment trends. Panelists will examine the long term landscape discussing how deliberate study planning and protocol optimizing DCTs effectively will differ than the 'ad hoc' use of services during COVID and how DCTs are creating diversity in clinical trials.

Participants

Moderator: Maria Fotiu - Executive VP of Decentralized Solutions, Syneos Health

Panelist: Cathy Gao - VP, Sapphire Venture

Panelist: Michelle Longmire - Founder and CEO,

Medable

Panelist: Juliet Moritz - COO, Illingworth Research

The digital healthcare revolution

On demand

Digital Medicine & Medtech Showcase

The COVID-19 pandemic led to an influx of market adaption and funding for digital health technologies this past year. From telemedicine and virtual clinical trials, to remote patient monitoring and digital therapeutics, digital health technologies are here to stay and will forever play a critical role in the way we treat and cure diseases. This panel will explore partnering and investment trends, the regulatory landscape, the cutting-edge digital health technologies transforming healthcare, discussing ultimately what this all means for patients, payers, digital health companies and investors.

Participants

Moderator: Jodi Scott - Partner, Hogan Lovells US LLP

Panelist: Bill Evans - CEO, Rock Health

Panelist: Douglas Lee - VP, Business Development & Licensing Head Digital & Data Science, Bayer U.S. Pharmaceuticals

Panelist: Beth Rogozinski - CEO, Oncoustics

Digital health's investment outlook

On demand

Digital Medicine & Medtech Showcase

Money poured into the digital health sector in 2020 as COVID-19 pushed digital health technologies to the forefront of care. This panel will reflect on this past year's funding trends and discuss where investors are placing their bets in the future.

Participants

Moderator: Logan Plaster - Director and Editor-in-Chief, StartUp Health

Panelist: Katya Hancock - Investment Network Director, StartUp Health

Panelist: Alyssa Jaffee - Partner, 7wireVentures

Panelist: Laura Veroneau - Partner, Optum Ventures



SCHEDULE
DIGITAL MEDICINE AND MEDTECH SHOWCASE ON DEMAND -

TIME	DIGITAL MEDICINE & MEDTECH SHOWCASE	
8:00AM	On demand - Digital tools revolutionizing mental health treatment	
9:00AM	On demand - Interview with the FDA's Bakul Patel	
10:00AM	On demand - Interview with Venrock's Bryan Roberts	
11:00AM	On demand - Interview with Medable's Michelle Longmire	
12:00PM	On demand - Investment, Commercialization, and Value Recognition: The AI Healthcare Hurdle	
1:00PM	On demand - Medtech's role in a transformed future	
2:00PM	On demand - Other doors: Backdoors, side doors, and alternative ways to fund and partner your technology	
3:00PM	On demand - Telemedicine: Enabling virtual and hybrid care post COVID-19	
4:00PM	4:30pm - The digitization of clinical trials	
5:00PM	On demand - The digital healthcare revolution	
6:00PM	On demand - Digital health's investment outlook	

SESSIONS
SEED SHOWCASE -

Official event dates: January 11–15, 2021 Post-show access until March 31, 2021

Seed Financing: Value Creation - Laying the foundation to raise money

On demand Seed Showcase

All innovative companies have to lay a foundation to position their company to raise the money that will eventually be needed to advance development programs. At the seed stage, laying that foundation includes intellectual property protection, demonstrating credibility by attracting grant monies for their program, and by understanding and articulating growth plans. Successful innovators also understand the importance of learning from others and surrounding their company with advisors who can guide them.

Participants

Moderator: Ben Johnson - Head of Early Stage Life Science, Silicon Valley Bank

Panelist: Stephen Flaim - Senior Special Advisor and Investor-in-Residence, National Institutes of Health

Panelist: Beth Hoffman - Founder and CEO, Origami Therapeutics, Inc.

Panelist: Tomas Landh - Innovation Sourcing VP, Senior Principal Scientist, Novo Nordisk

Panelist: Jon Layman - Partner, Hogan Lovells

Panelist: Una S. Ryan - Managing Director, Golden Seeds





TIME	SEED SHOWCASE	
8:00AM	On demand - Seed Financing: Value Creation - Laying the foundation to raise money	